drugset / Trial / NCT01970449
Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults
Phase 1
Withdrawn
National Institute of Allergy and Infectious Diseases (NIAID)
Center for HIV/AIDS Vaccine Immunology (CHAVI) · collabHIV Vaccine Trials Network · collabIPPOX Foundation · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this study is to test the safety and immune response to three different sets of HIV vaccines in healthy, HIV-uninfected adults.
Timeline
- Start
- —
- Primary completion
- 2018-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DNA CON-S env vaccine | Vaccine | 4 mg | Intramuscular |
| Subject | DNA Mosaic env vaccine | Vaccine | 4 mg | Intramuscular |
| Subject | DNA Nat-B env vaccine | Vaccine | 4 mg | Intramuscular |
| Subject | NYVAC CON-S env vaccine | Vaccine | 3e+07 unknown | Intramuscular |
| Subject | NYVAC Mosaic env vaccine | Vaccine | 3e+07 unknown | Intramuscular |
| Subject | NYVAC Nat-B env vaccine | Vaccine | 3e+07 unknown | Intramuscular |